Journal of Endocrinological Investigation

, Volume 6, Issue 2, pp 125–128 | Cite as

Nomifensine decreases the thyroid-stimulating-hormone response to thyrotropin-releasing-hormone in normal subjects

  • M. Giusti
  • G. Mazzocchi
  • D. Mignone
  • W. Tarditi
  • G. Giordano


The Thyroid-stimulating-hormone (TSH) secretion has been studied in 12 normal euthyroid subjects (4 males, 8 females) after nomifensine (NOM) administration (200 μg po). NOM is a drug which activates dopaminergic neurotransmission at the Central Nervous System level. Blood samples were drawn every h for4 h after NOM or placebo, respectively. At the4th hour thyrotropin-releasing-hormone (TRH) was administered in bolus (200 jug iv), in both studies, and additional samples were collected for 90 min. The results show a moderate suppression (NS) of TSH and a clear-cut reduction in the secretory response to TRH after NOM administration (secretory area: TRH after placebo 723 ± 132, TRH after NOM 400 ± 83; p < 0.01 ). The data appear to confirm that dopaminergic neurotransmission exerts an inhibitory role upon TSH secretion. The mechanism by which NOM induced dopaminergic activation leads to the suppression of TSH release after TRH has not yet been elucidated. An interference in TSH storage and/or in the post receptor mechanisms involved in TRH action might be hypothesized.


Normal subjects TSH secretion TRH nomifensine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hunt P., Kannengiesser M.H., Raynaud J.P. Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum. J. Pharm. Pharmacol. 26: 370,1974.PubMedCrossRefGoogle Scholar
  2. 2.
    Braestrup C., Scheel-Krüger J. Methylphenidate-like effects of the new antidepressant drug nomifensine (HOE 984). Eur. J. Pharmacol. 38: 305,1976.PubMedCrossRefGoogle Scholar
  3. 3.
    Gerhards H.J., Carenzi A., Costa E. Effect of nomifensine on motor activity, dopamine turn over rate and cyclic 3′5′-adenosine monophosphate concentration of rat striatum. Naunyn-Schmiedebergs Arch. Pharmacol. 286: 49, 1974.PubMedCrossRefGoogle Scholar
  4. 4.
    Genazzani A.R., Camanni F., Massara F., Picciolini E., Cocchi D., Belforte L, Müller E.E. A new pharmacological approach to the diagnosis of hyperprolactinemic states: the nomifensine test. Acta Endocrinol. (Kbh.) 93: 139, 1980.Google Scholar
  5. 5.
    Müller E.E., Genazzani A.R., Murru S. Nomifensine: diagnostic test in hyperprolactinemic states. J. Clin. Endocrinol. Metab. 47: 1352, 1978.PubMedCrossRefGoogle Scholar
  6. 6.
    Laakmann G., Benkert O. Effects of antidepressants on pituitary hormones. Próc. of Symposium on depressive disorders. Hoechst Symposia N 13: Rome may 9–11, 1977; F.K. Scattauer Verlag, Stuttgart-New York, p. 225 (Abstract).Google Scholar
  7. 7.
    Masala A., Alagna S., Devilla L., Dentala G., Rovasio P.P. Inhibition on prolactin secretion by nomifensine in man. Clin. Endocrinol. (Oxf.) 12: 237, 1980.CrossRefGoogle Scholar
  8. 8.
    Scanlon M.F., Gomez-Pan A., Mora B., Cook D.B., Dewar J.H., Hildyard A., Weightman D.R., Evered D.C., Hall R. Effects of nomifensine, an inhibitor of endogenous catecholamines re-uptake, in acromegaly, in hyperprolac-tinaemia and against stimulated prolactin release in man. Br. J. Clin. Pharmacol. 4: (Suppl. 2): 191, 1977.CrossRefGoogle Scholar
  9. 9.
    Ferrari G., Crosignani P.G., Caldara R., Piciotti M.C., Malinverni A., Barattini B., Rampini P., Tellolli P. Failure of nomifensine administration to discriminate be tween tumorous and nontumorous hyperprolactinaemia. J. Clin. Endocrinol. Metab. 50: 23, 1980.PubMedCrossRefGoogle Scholar
  10. 10.
    Minuto F., Bernasconi D., Barreca A., Grimaldi G.P., Ferrini S., Giordano G. Effetto della nomifensina sulla secrezione somatotropinica nell’uomo. J. Endocrinol. Invest. 4 (Suppl. 1 ): 97, 1981.Google Scholar
  11. 11.
    Basses G.S., Burrow G.N., Spaulding S.W., Donabedian R.K. Dopamine infusion acutely inhibits the TSH and prolactin response to TRH. J. Clin. Endocrinol. Metab. 41: 985,1975.CrossRefGoogle Scholar
  12. 12.
    Massara F., Camanni F., Vergano V., Belforte C, Molinatti G.M. Inhibition of thyrotropin and prolactin secretion by dopamine in man. J. Endocrinol. Invest. 1: 29, 1978.Google Scholar
  13. 13.
    Delitala G., Wass J.H.A., Stubbs WA, Jones A., Williams S., Besser G.M. The effect of lisuride hydrogen meleate, and ergot derivative, on anterior pituitary hormone secretion in man. Clin. Endocrinol. (Oxf.) 11: 1, 1979.CrossRefGoogle Scholar
  14. 14.
    Yap P.L., Mc Davidson N., Lidgard G., Pfyffe J.A. Bromocryptine suppression of the thyrotrophin re sponse to Thyrotrophin releasing hormone. Clin. Endocrinol. (Oxf.) 9: 179, 1978.CrossRefGoogle Scholar
  15. 15.
    Miyai K., Onishi T., Hosokawa M., Ishibashi K., Kumahara Y. Inhibition of thyrotropin and prolactin secretion in primary hypothyroidism by 2-Br-a-ergocryptine. J. Clin. Endocrinol. Metab. 39: 391, 1974.CrossRefGoogle Scholar
  16. 16.
    Massara F., Camanni F., Belforte L, Vergano V., Molinatti M. Increased thyrotrophin secretion induced by sulphiride in man. Clin. Endocrinol. (Oxf.) 9: 419, 1978.CrossRefGoogle Scholar
  17. 17.
    Scanlon M.F., Mora B., Shale D.J., Weightman D.R., Heath M., Snow M.H., Hall R. Evidence for dopaminergic control of thyrotrophin (TSH) secretion in man. Lancet 2: 421, 1977.PubMedCrossRefGoogle Scholar
  18. 18.
    Delitala G., Devilla L, Canessa A., D’Asta F. On the role of dopamine receptors in the central regulation of human TSH. Acta Endocrinol. (Kbh.) 98: 521, 1981.Google Scholar
  19. 19.
    Pourmand M., Rodriguez-Arnao M.D., Weightman D.R., Hall R., Cook D.B., Lewis M., Scanlon M.F. Domperidone: a novel agent for the investigation of an terior pituitary function and control in man. Clin. Endocrinol. (Oxf.) 72:211,1980.CrossRefGoogle Scholar
  20. 20.
    Reichlin S., Martin J.B., Jackson I.M.D. Regulation of thyroid-stimulating hormone (TSH) secretion. In: Jeffcoate S.L., Hutchinson J.S.M. (Eds.), The endocrine hypothalamus. Academic Press, New York, 1978, p. 229.Google Scholar
  21. 21.
    Hirvonen E., Ranta T., Seppälä A. Prolactin and thyrotropin responses to thyrotrophin-re- leasing hormone in patients with secondary amenorrhoea, the effect of bromocriptine. J. Clin. Endocrinol. Metab. 42: 1024, 1976.PubMedCrossRefGoogle Scholar
  22. 22.
    Refetoff S., Fang V.S., Rapaport B., Friesen H.G. Interrelationships in the regulation of TSH and prolactin secretion in man: effects of L-dopa, TRH and thyroid hormone in various combinations. J. Clin. Endocrinol.Metab. 38: 450, 1974.PubMedCrossRefGoogle Scholar
  23. 23.
    Scanlon M.F., Weightman D.R., Shale D.J., Mora B., Heath M., Snow M.H., Hall R. Dopamine is a physiological regulator of thyrotrophin (TSH) secretion in normal man. Clin. Endocrinol. (Oxf.) 10: 7, 1979.CrossRefGoogle Scholar
  24. 24.
    Brown G.M., Seeman P., Lee T. Dopamine-neuroleptic receptors in the basal hypotha lamus and pituitary. Endocrinology 99: 1407, 1979.CrossRefGoogle Scholar
  25. 25.
    Kellner H.M., Baeder C, Christ O., Heptner W. Hornke I., Ings R.M.J. Kinetics and metabolism of nomifensine in animals. Br. J. Clin. Pharmacol. 4: 109S, 1977.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Sassin J.F., Frantz A.G., Kapen S., Weitzman E.D. The nocturnal rise of human prolactin is dependent on sleep. J. Clin. Endocrinol. Metab. 37: 436, 1973.PubMedCrossRefGoogle Scholar
  27. 27.
    Noel G.L. Human prolactin and growth hormone release during surgery and other conditions of stress. J. Clin. Endocrinol. Metab. 35: 840,1972.PubMedCrossRefGoogle Scholar
  28. 28.
    Quigley M.E., Judd S.J., Gilliland J.B., Yen S.S.C. Functional studies of dopamine control of prolactin se cretion in normal women and women with hyperprolactinemic pituitary microadenoma. J. Clin. Endocrinol. Metab. 50: 994, 1980.PubMedCrossRefGoogle Scholar
  29. 29.
    Ishibaschi M., Yamaji T., Kosaka K. Effect of bromocryptine on TRH-induced growth hormone and prolactin release in acromegalic patients. J. Clin. Endocrinol. Metab. 45: 275, 1977.CrossRefGoogle Scholar
  30. 30.
    Rabey J.M., Vardi Y., Ravid R., Ayalon D. Dissociation of thyrotrophin releasing hormone stimula tion in L-Dopa treated parkinsonian patients. Horm. Res. 75: 78, 1981.CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1983

Authors and Affiliations

  • M. Giusti
    • 1
  • G. Mazzocchi
    • 1
  • D. Mignone
    • 1
  • W. Tarditi
    • 1
  • G. Giordano
    • 1
  1. 1.Cattedra di EndocrinologiaUniversità di GenovaGenovaItaly

Personalised recommendations